HOUSTON INNOVATORS PODCAST EPISODE 52

Houston scientist taps nanotech in masks and air filters to use to prevent COVID-19 spread

University of Houston professor and entrepreneur, Seamus Curran, has pivoted amid the pandemic to use his nanotechnology expertise to help reduce the spread of COVID-19. Photo courtesy of Integricote

For over a decade, Seamus Curran, a physics professor at the University of Houston, has worked on his nanotechnology coating substance. He first thought the innovation could be used on fabrics and textile coating, but he realized, once getting acquainted with the industry, he realized there wasn't an interest for a hydrophobic coating that could be used to prevent the spread of germs — at least, not yet.

"Like anything small startup company, one of the things you have to learn is you have to pivot — or you will die," says Curran, who had created his company Integricote (neé C-Voltaics) to take his innovation to market.

So pivot is what he did. Integricote now markets toward coating and sealing materials within the construction industry — wood, concrete, etc. — to protect from water damage and rotting. As Curran shares on this week's episode of the Houston Innovators Podcast, business was growing steadily. That is until COVID-19 hit.

His construction coating business slowed, much like the rest of business across the country, and classes at UH switched to online. Curran used this newfound time at home to dig deeper into the details of the virus, when an idea hit him.

"I learned the virus traveled in a wet medium," Curran says, "(our coating) is hydrophobic, meaning we can stop it from penetrating any fabrics."

Curran worked to create hydrophobic facemasks using his sealant, and the technology was lauded and covered by various news organizations. He created a new company under Integricote, called Curran Biotech, and he started thinking of the next pandemic-proof innovation he could create using his sealant.

"The big thing for me when we were shut down was that people couldn't go to work or school. The country can't live that way — but you can't send people back to work in a world that's not safe," Curran says. "How do you create a safer environment? That's the thing that really got me going in the beginning in the summer. We looked at filters."

Curran, learning more about air filters than he ever cared to, realized that even the most expensive air filters can only protect from 10 to 25 percent of viruses. And most buildings' HVAC systems would have to be replaced completely to allow for these pricier, more protective filters.

"So, you'd have to replace your equipment and your filter prices go up — and you're still not blocking the virus," Curran says.

Curran Biotech's solution is a spray coating that can be used on air filters to make them more protected from COVID-19 spread.

Curran shared more about his nanotechnology innovation — as well as his excitement for being named one of MassChallenge Texas's finalist within the 2020 Houston cohort — in the episode of the podcast. You can listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Trending News

Building Houston

 
 

Dr. Peter Hotez and Dr. Maria Elena Bottazzi have been recognized by Fast Company for their leadership in developing low-cost COVID vaccine. Photo courtesy of Texas Children's

This week, Fast Company announced its 14th annual list of Most Creative People in Business — and two notable Houstonians made the cut.

Dr. Peter Hotez and his fellow dean of the National School of Tropical Medicine at Baylor College of Medicine, Dr. Maria Elena Bottazzi, were named among the list for “open sourcing a COVID-19 Vaccine for the rest of the world.” The list, which recognizes individuals making a cultural impact via bold achievements in their field, is made up of influential leaders in business.

Hotez and Bottazzi are also co-directors for the Texas Children's Hospital's Center for Vaccine Development -one of the most cutting-edge vaccine development centers in the world. For the past two decades it has acquired an international reputation as a non-profit Product Development Partnership (PDP), advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. One of their most notable achievements is the development of a vaccine technology leading to CORBEVAX, a traditional, recombinant protein-based COVID-19 vaccine.

"It's an honor to be recognized not only for our team's scientific efforts to develop and test low cost-effective vaccines for global health, but also for innovation in sustainable financing that goes beyond the traditional pharma business model," says Hotez in a statement.

The technology was created and engineered by Texas Children's Center for Vaccine Development specifically to combat the worldwide problem of vaccine access and availability. Biological E Limited (BE) developed, produced and tested CORBEVAX in India where over 60 million children have been vaccinated so far.

Earlier this year, the doctors were nominated for the 2022 Nobel Peace Prize for their research and vaccine development of the vaccine. Its low cost, ease of production and distribution, safety, and acceptance make it well suited for addressing global vaccine inequity.

"We appreciate the recognition of our efforts to begin the long road to 'decolonize' the vaccine development ecosystem and make it more equitable. We hope that CORBEVAX becomes one of a pipeline of new vaccines developed against many neglected and emerging infections that adversely affect global public health," says Bottazzi in the news release from Texas Children's.

Fast Company editors and writers research candidates for the list throughout the year, scouting every business sector, including technology, medicine, engineering, marketing, entertainment, design, and social good. You can see the complete list here

.

Trending News